Previous Next


№2' 2021


International Medical Journal, Vol. 27., Iss. 2, 2021, P. 10−15.



Maryna Mykolayivna Kochuieva, Shklyar S. P., Tymchenko H. A., Kochuiev H. I., Khodosh E. M., Valentyna Hryhorivna Psarova, Yakovenko O. L.

Kharkiv Medical Academy of Postgraduate Education, Ukraine
Sumy State University, Ukraine

Identifying the risk groups with potentially higher susceptibility and worse prognosis is an important to combat the COVID−19. Bronchial asthma is a common non−infectious disease of the respiratory system, and this group of patients is usually prone to more severe consequences of viral infections. Already at the early stages of the COVID−19 pandemic, this pathology was classified as a comorbid which can potentially increase the risk of coronavirus infection and worsen its course. However, recent scientific evidence suggests that the prevalence of allergic diseases and asthma among those infected is lower than expected compared to other comorbidities. Analysis of the results of most studies shows that patients with COVID−19 have concomitant bronchial asthma with no increased risk of hospitalization, admission to the intensive care unit, intubation / ventilation, higher clinical severity or mortality than the patients without bronchial asthma. This may be due to the pathogenetic mechanisms of allergic reaction and the use of inhaled corticosteroids. Considering the effect of asthma therapy on the course of COVID−19, the researchers found that the systematic use of inhaled corticosteroids reduces the incidence of exacerbations of bronchial asthma, allergen immunotherapy may play a protective role in very ill patients with COVID−19. Studies indicate a potential effect of monoclonal antibodies against IgE on the viral response. Taking into account the potential protective effects of bronchial asthma treatment and the high risk of its exacerbations when basic therapy is discontinued, as well as following the GINA 2020 guidelines for the management of such patients in COVID−19, the authors consider appropriate its prescribing during a pandemic.

Key words: COVID−19, SARS− CoV−2, bronchial asthma, pathogenesis, inhaled corticosteroids.


1. WHO Coronavirus Disease (COVID−19) Dashboard. URL:

2. Coronavirus in Ukraine. URL: coronavirus/ukraine/

3. GINA: Interim Guidance about COVID−19 and Asthma, updated 20 Dec 2020. URL:

4. Molecular detection of respiratory pathogens and typing of human rhinovirus of adults hospitalized for exacerbation of asthma and chronic obstructive pulmonary disease / F. W. Ko et al. // Respir. Res. 2019. Vol. 20. P. 210. doi:−019−1181−0

5. Regional, age and respiratory−secretion−specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review / X. Y. Zheng et al. // Arch. Virol. 2018. Vol. 163. P. 845−853. doi:−017−3700−y

6. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study / N. Chen et al. // Lancet. 2020. Vol. 395 (10223). P. 507−513. doi: 10.1016/S0140−6736(20)30211−7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.

7. Risk factors for severity and mortality in adult COVID−19 in patients in Wuhan / X. Li et al. // J. Allergy Clin. Immunol. 2020. Vol. 146 (1). P. 110−118. doi: 10.1016/j.jaci.2020.04.006

8. Prevalence, risk factors, and management of asthma in China: a national cross−sectional study / K. Huang et al. // Lancet. 2019. Vol. 394 (10196). P. 407−418. doi: 10.1016/S0140−6736(19)31147−X

9. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID−19) in China / Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention // Zhonghua Liu Xing Bing Xue Za Zhi. 2020. Vol 41 (2) P. 145−151. doi: 10.3760/cma.j.issn.0254−6450.2020.02.003

10. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID−19 in the New York City area / S. Richardson et al. // JAMA. 2020. Vol. 323 (20). P. 2052−2059. doi: 10.1001/jama.2020.6775

11. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID−19 / K. D. Chhiba et al. // J. Allergy Clin Immunol. 2020. Vol. 146 (2). P. 307−314.e4. doi: 10.1016/j.jaci.2020.06.010

12. Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID‐19 patients. Preprint / A. Mendy et al. // medRxiv. doi:10.1101/2020.06.25.20137323

13. Prevalence of comorbid asthma and related outcomes in COVID−19: A systematic review and meta−analysis / S. Liu et al. // J. Allergy Clin. Immunol Pract. 2021. Vol. 9 (2). P. 693−701. doi: 10.1016/j.jaip.2020.11.054

14. The association between COVID−19 and asthma: A systematic review and meta−analysis / Y. Wang et al. // Clin. Exp. Allergy. 2020. Vol. 50 (11). P. 1274−1277. doi: 10.1111/cea.13733

15. Association of asthma and its genetic predisposition with the risk of severe COVID−19 / Z. Zhu et al. // J. Allergy Clin. Immunol. 2020. Vol. 146 (2). P. 327−329.e4. doi: 10.1016/j.jaci.2020.06.001.

16. Asthma in COVID−19 patients: An extra chain fitting around the neck? / M. H. Hussein et al. // Respir. Med. 2020. Vol. 175. P. 106205. doi: 10.1016/j.rmed.2020.106205

17. COVID−19 susceptibility in bronchial asthma / I. Green et al. // J. Allergy Clin. Immunol. Pract. 2021. Vol. 9 (2). P. 684−692. doi: 10.1016/j.jaip.2020.11.020

18. Asthma prolongs intubation in COVID−19 / M. Mahdavinia et al. // J. Allergy Clin. Immunol. Pract. 2020. Vol. 8 (7). P. 2388−2391. doi:10.1016/j.jaip.2020.05.006

19. Coronavirus infections and immune responses / G. Li et al. // J. Med. Virol. 2020. Vol. 92 (4). P. 424−432. doi:

20. Host factors in coronavirus replication / A. H. de Wilde et al. // Curr. Top. Microbiol. Immunol. 2018. Vol. 419. P. 1−42. doi:

21. The use of anti−inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID−19): the perspectives of clinical immunologists from China / W. Zhang et al. // Clin. Immunol. 2020. Vol. 214. P. 108393. doi:

22. Gonzales−van Horn S. R., Farrar J. D. Interferon at the crossroads of allergy and viral infections // J. Leukoc. Biol. 2015. Vol. 98 (2). P. 185−194. doi:−099R

23. Liu S., Zhi Y., Ying S. COVID−19 and asthma: reflection during the pandemic // Clin. Rev. Allergy Immunol. 2020. Vol. 59 (1). P. 78−88. doi: 10.1007/s12016−020−08797−3. PMID: 32468411.

24. Halpin D. M., Singh D., Hadfield R. M. Inhaled corticosteroids and COVID−19: a systematic review and clinical perspective / Eur. Respir. J. 2020. Vol. 55 (5). P. 2001009. doi:10.1183/13993003.01009−2020

25. Risk of COVID−19−related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform / A. Schultze et al. // Lancet Respir. Med. 2020. Vol. 8 (11). P. 106−1120. doi: 10.1016/S2213−2600(20)30415−X

Go on Top